Balaxi Pharmaceuticals Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN L25191TG1942PLC121598 Incorporated 28 September 1942 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: BALAXI Public Limited Company pharma MSME
Market Cap
₹146 Cr
BALAXI · NSE
Share Price
₹31.65
+19.57% today
Revenue
₹270 Cr
FY 2025-26 · -7.7% YoY
EBITDA
₹8.52 Cr
Margin 3.1%
Net Profit
₹1.42 Cr
FY 2025-26 · -94.4% YoY
P/E (TTM)
36.2x
P/B 0.5x
ROE
0.6%
ROCE 3.5%
Debt / Equity
0.23
Interest cover 66.8x

About Balaxi Pharmaceuticals Limited

Data last updated:

Balaxi Pharmaceuticals Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Balaxi Overseas Private Limited. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 28 September 1942 and has been in existence for over 84 years.

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L25191TG1942PLC121598. Its GSTIN is 36AABCA8305N1ZJ (Telangana). The company holds 2 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on NSE: BALAXI.

The company has an authorised share capital of ₹40 Cr and a paid-up capital of ₹11.04 Cr. It was formerly known as Balaxi Ventures Limited and Anandam Rubber Company Limited. It is led by directors including Ashish Maheshwari (Managing Director) and Mangina Srinivas Rao.

Its last annual general meeting (AGM) was held on 25 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Hyderabad, Telangana.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹270.17 Cr, a decline of 7.7% compared to the previous year. For the same year it recorded a net profit of ₹1.42 Cr (net margin 0.5%) and EBITDA of ₹8.52 Cr (EBITDA margin 3.2%). The net worth stands at ₹249.07 Cr (up 7.5% YoY). Total assets are valued at ₹306.97 Cr (up 7.6% YoY).

The company has about 80 employees on its provident fund (EPFO) records.

The company is associated with 3 brands: Balaxi Pharmaceuticals, Anandam Rubber Company and Balaxi. As per MCA filings, the company has open charges of ₹36.44 Cr and satisfied charges of ₹34.29 Cr on record. Court records list 1 case involving the company, including 1 filed by the company; 1 case is pending. The company has 13 deals on record (12 market trades, 1 funding round), with disclosed funding of ₹49.61 Cr; the latest was in March 2026. The company has 5 MSME Form 1 returns on record between 2023 and 2024, listing 368 overdue payments to 13 micro and small suppliers.

Balaxi Pharmaceuticals Limited is registered as an MSME under the Udyam registration framework (Reg. No. UDYAM-TS-02-0041664). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website balaxiventures.in.

Company details

CIN L25191TG1942PLC121598
Registration Number 121598
Incorporation Date 28 September 1942
ROC Hyderabad
Listing Status Listed - Listed on NSE (BALAXI)
Company Status Active
Parent Company Balaxi Overseas Private Limited
Compliance Status Active Compliant
MSME Classification MSME
Udyam Registration UDYAM-TS-02-0041664

Name history

Balaxi Pharmaceuticals has undergone 3 name changes throughout its history. The company was previously known as Balaxi Ventures Limited, Anandam Rubber Company Limited, and The Anandam Rubber Company Limited. The current legal name is Balaxi Pharmaceuticals Limited.

Company NameStatus
Balaxi Pharmaceuticals LimitedCurrent
Balaxi Ventures LimitedPrevious
Anandam Rubber Company LimitedPrevious
The Anandam Rubber Company LimitedPrevious

CIN history

Balaxi Pharmaceuticals has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L25191TG1942PLC121598, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L25191TG1942PLC121598Current
U25191KL1942PLC000045Previous
L25191KL1942PLC000045Previous

Recognitions & Rankings of Balaxi Pharmaceuticals

MSME (Udyam registered) Ministry of MSME
Udyam number
UDYAM-TS-02-0041664

Contact details

Balaxi Pharmaceuticals Limited's registered office is in Hyderabad, Telangana. Its website is balaxiventures.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Social Media
  • Registered Address
    Plot No.409 H.No. 8 – 2 – 293 Maps Towers 3rd Floor Phase – III Road No.81 Jubilee, Hills, Hyderabad, Telangana, India – 500096
  • Industry
    Pharma, Pharmaceutical Retailers & Distributors

To see the full contact details of Balaxi Pharmaceuticals Limited, buy the company report.

Comprehensive company report
Balaxi Pharmaceuticals Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Balaxi Pharmaceuticals operates multiple associated brands including Balaxi Pharmaceuticals, Anandam Rubber Company, and Balaxi. Each brand links to its own profile.

BrandDescriptionWebsite
Agricultural operations, grain marketing, and equipment services by Balaxi.balaxiventures.in
Fabricated metal products are manufactured by Anandam Rubber Company.anandamrubberco.com
Drug distribution and storage services are provided by Balaxi.balaxipharma.in

Business activity

The main business activity of Balaxi Pharmaceuticals is wholesale and retail trade; repair of motor vehicles and motorcycles. In detail, this covers wholesale trade, except of motor vehicles and motorcycles.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
GWholesale and retail trade; repair of motor vehicles and motorcycles46Wholesale trade, except of motor vehicles and motorcycles

To see the full business activity and turnover split of Balaxi Pharmaceuticals Limited, buy the company report.

Financials of Balaxi Pharmaceuticals Limited

FY 2025-26 filings available

Balaxi Pharmaceuticals Limited reported revenue of ₹270.17 Cr (down 7.7% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹270 Cr
-7.7% YoY
EBITDA
₹8.52 Cr
-73.6% YoY
Profit After Tax
₹1.42 Cr
-94.4% YoY
Net Worth
₹249 Cr
+7.5% YoY
Total Assets
₹307 Cr
+7.6% YoY
Total Debt
₹57.65 Cr
+7.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue27029324133627923145.63
Revenue growth-7.7%+21.3%-28.3%+20.4%+20.8%+407.0%-
EBITDA8.5232.226.2357.4150.8142.678.25
EBITDA margin+3.2%+11.0%+2.6%+17.1%+18.2%+18.5%+18.1%
Profit before tax5.2928.681.9956.9254.5144.328.78
Net profit1.4225.16(49.85)45.9647.6538.136.09
Net profit margin+0.5%+8.6%-20.7%+13.7%+17.1%+16.5%+13.4%
EPS (₹)0.264.54(0.44)45.1447.6638.146.10
Balance sheet
Total assets30728522119611768.6427.75
Net worth24923220118311364.9827.75
Total debt57.6553.4319.4013.303.643.660.00
Cash & bank14.5639.4062.2928.227.191.674.00
Net working capital22321917415181.3762.7426.62
Cash flow
Cash from operations(4.50)(35.00)4.876.0834.140.00(14.04)
Cash from investing(20.78)(21.76)(1.05)(10.57)(28.45)(5.97)(0.18)
Cash from financing0.4433.8830.2525.51(0.16)3.6518.10
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue81.3780.6870.7172.5456.1870.7476.2773.29
Revenue growth (YoY)+44.8%+14.1%-7.3%-1.0%-27.4%+7.8%--
Other income(0.83)(0.99)2.920.101.59(1.78)(1.69)3.94
EBITDA5.124.660.123.091.174.1512.563.99
EBITDA margin+6.3%+5.8%+0.2%+4.3%+2.1%+5.9%+16.5%+5.4%
Depreciation1.420.850.650.560.480.460.460.48
Interest0.860.730.991.020.891.010.741.38
Profit before tax2.012.091.401.611.390.909.676.07
Tax0.870.800.791.301.160.611.020.71
Net profit1.141.290.610.310.230.298.655.36
EPS (₹)0.210.240.110.060.040.051.560.97
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue80.8560.9970.2010810186.8745.63
Revenue growth+32.6%-13.1%-35.1%+6.8%+16.6%+90.4%-
EBITDA0.762.615.3516.8717.3019.028.65
EBITDA margin+0.9%+4.3%+7.6%+15.6%+17.1%+21.9%+19.0%
Profit before tax7.035.285.5822.4419.7020.599.18
Net profit5.153.603.6916.2114.6715.136.49
Net profit margin+6.4%+5.9%+5.3%+15.0%+14.5%+17.4%+14.2%
EPS (₹)0.930.650.6715.9314.6715.136.50
Balance sheet
Total assets16916013710559.8446.7528.11
Net worth13312812292.1157.9143.2528.11
Total debt35.2932.1815.7012.441.933.510.00
Cash & bank5.3328.6944.0617.880.840.483.57
Net working capital48.3110610774.9432.0426.5226.91
Cash flow
Cash from operations43.87(7.60)(1.83)(7.07)8.8913.46(14.37)
Cash from investing(67.77)(24.98)0.46(2.29)(6.87)(20.03)(0.28)
Cash from financing0.5417.2127.5526.39(1.64)3.4918.10
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue26.2915.5820.2424.5919.3116.719.6511.16
Revenue growth (YoY)+36.2%-6.8%+109.7%+120.3%-8.7%-12.2%--
Other income1.080.923.371.624.210.460.322.92
Total expenses25.9616.5822.1723.2118.5416.1710.3011.06
EBITDA0.33(1.00)(1.93)1.380.770.54(0.65)0.10
EBITDA margin+1.3%-6.4%-9.5%+5.6%+4.0%+3.2%-6.7%+0.9%
Depreciation0.590.590.310.150.120.110.110.11
Interest0.570.450.710.730.620.630.690.57
Profit before tax0.25(1.12)0.422.124.240.26(1.13)2.34
Tax0.140.140.260.590.970.060.040.59

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 18 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue81.3780.6870.7172.5456.1870.7476.2773.29
Revenue growth (YoY)+44.8%+14.1%-7.3%-1.0%-27.4%+7.8%--
Other income(0.83)(0.99)2.920.101.59(1.78)(1.69)3.94
EBITDA5.124.660.123.091.174.1512.563.99
EBITDA margin+6.3%+5.8%+0.2%+4.3%+2.1%+5.9%+16.5%+5.4%
Depreciation1.420.850.650.560.480.460.460.48
Interest0.860.730.991.020.891.010.741.38
Profit before tax2.012.091.401.611.390.909.676.07
Tax0.870.800.791.301.160.611.020.71
Net profit1.141.290.610.310.230.298.655.36
EPS (₹)0.210.240.110.060.040.051.560.97
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue27029324133627923145.63
Revenue growth-7.7%+21.3%-28.3%+20.4%+20.8%+407.0%-
Other income2.822.360.632.644.972.230.59
Total expenses26226023527922918937.38
Employee cost0.0034.7428.0428.9512.478.472.10
EBITDA8.5232.226.2357.4150.8142.678.25
EBITDA margin+3.2%+11.0%+2.6%+17.1%+18.2%+18.5%+18.1%
Depreciation2.151.892.101.750.510.300.01
Interest3.904.012.771.380.760.280.05
Profit before tax5.2928.681.9956.9254.5144.328.78
Tax3.873.604.4010.966.866.192.69
Net profit1.4225.16(49.85)45.9647.6538.136.09
Net profit margin+0.5%+8.6%-20.7%+13.7%+17.1%+16.5%+13.4%
EPS (₹)0.264.54(0.44)45.1447.6638.146.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11.0411.0410.9010.1810.0010.0010.00
Reserves & surplus23822118716210354.9817.75
Shareholders' funds (net worth)24923220118311364.9827.75
Minority interest0.000.000.000.000.000.000.00
Secured loans1.300.000.000.070.130.150.00
Unsecured loans56.3553.4319.4013.233.513.510.00
Total debt57.6553.4319.4013.303.643.660.00
Total liabilities30728522119611768.6427.75
Assets
Gross block85.8142.8842.9843.0029.232.740.19
Net block81.6840.9940.8841.4028.762.440.19
Capital work in progress0.0022.072.312.830.570.000.00
Investments0.000.000.000.000.003.420.00
Inventories83.4878.4882.1710598.7013.620.83
Sundry debtors13611155.7152.2827.5676.7629.71
Cash & bank balances14.5639.4062.2928.227.191.674.00
Loans & advances17.2914.0910.017.997.551.720.31
Total current assets25124321019414193.7734.85
Total current liabilities28.7324.1536.5342.3959.6331.038.23
Net working capital22321917415181.3762.7426.62
Total assets30728522119611768.6427.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash39.4062.2928.217.191.663.980.10
Net cash from operating activities(4.50)(35.00)4.876.0834.140.00(14.04)
Net cash from investing activities(20.78)(21.76)(1.05)(10.57)(28.45)(5.97)(0.18)
Net cash from financing activities0.4433.8830.2525.51(0.16)3.6518.10
Net change in cash(24.84)(22.89)34.0721.025.53(2.32)3.88
Closing cash14.5639.4062.2928.227.191.674.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-7.7%+21.3%-28.3%+20.4%+20.8%+407.0%-
EBITDA growth-73.6%+417.2%-89.2%+13.0%+19.1%+417.2%-
PBT growth-81.6%+1340.7%-96.5%+4.4%+23.0%+404.8%+258.4%
Net income growth-94.4%+150.5%-208.5%-3.6%+25.0%+526.1%-
Revenue CAGR (3Y)-7.1%+1.6%+1.4%+94.6%+173.9%--
EBITDA CAGR (3Y)-45.0%-9.0%-47.3%+90.9%+219.4%--
Profitability & leverage
Net income margin+0.5%+8.6%-1.0%+13.7%+17.1%+16.5%+13.4%
Return on capital employed+3.5%+12.9%+20.7%+37.3%+59.6%+92.6%+56.5%
Return on net worth+0.6%+11.6%-25.9%+31.1%+53.5%+82.3%+39.0%
Debt / equity0.230.170.090.060.040.040.00
Long-term debt / equity0.100.060.010.010.000.000.00
Interest cover66.8511.0267.072.481.510.660.61
Efficiency & per share
Fixed asset turnover4.206.815.619.3217.48157.90456.30
Inventory turnover3.343.642.583.304.9732.02109.95
Debtors turnover2.193.514.478.435.364.352.59
EPS (₹)0.264.54(0.44)45.1447.6638.146.10
Dividend per share (₹)0.000.000.000.000.500.000.00
Book value per share (₹)45.1241.9836.26169.51113.1664.9827.75
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue26.2915.5820.2424.5919.3116.719.6511.16
Revenue growth (YoY)+36.2%-6.8%+109.7%+120.3%-8.7%-12.2%--
Other income1.080.923.371.624.210.460.322.92
Total expenses25.9616.5822.1723.2118.5416.1710.3011.06
EBITDA0.33(1.00)(1.93)1.380.770.54(0.65)0.10
EBITDA margin+1.3%-6.4%-9.5%+5.6%+4.0%+3.2%-6.7%+0.9%
Depreciation0.590.590.310.150.120.110.110.11
Interest0.570.450.710.730.620.630.690.57
Profit before tax0.25(1.12)0.422.124.240.26(1.13)2.34
Tax0.140.140.260.590.970.060.040.59
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue80.8560.9970.2010810186.8745.63
Revenue growth+32.6%-13.1%-35.1%+6.8%+16.6%+90.4%-
Other income9.675.372.406.602.751.810.59
Total expenses80.0958.3864.8591.2783.9967.8536.98
Employee cost0.004.875.044.042.901.951.75
EBITDA0.762.615.3516.8717.3019.028.65
EBITDA margin+0.9%+4.3%+7.6%+15.6%+17.1%+21.9%+19.0%
Depreciation0.700.460.510.520.250.090.01
Interest2.702.241.660.510.100.150.05
Profit before tax7.035.285.5822.4419.7020.599.18
Tax1.881.681.936.235.035.462.69
Net profit5.153.603.6916.2114.6715.136.49
Net profit margin+6.4%+5.9%+5.3%+15.0%+14.5%+17.4%+14.2%
EPS (₹)0.930.650.6715.9314.6715.136.50
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11.0411.0410.9010.1810.0010.0010.00
Reserves & surplus12211710771.6347.9133.2518.11
Shareholders' funds (net worth)13312812292.1157.9143.2528.11
Secured loans1.300.000.150.490.930.000.00
Unsecured loans33.9932.1815.5511.951.003.510.00
Total debt35.2932.1815.7012.441.933.510.00
Total liabilities16916013710559.8446.7528.11
Assets
Gross block42.077.137.618.412.450.780.19
Net block41.376.677.107.892.200.690.19
Capital work in progress0.0022.072.312.830.570.000.00
Investments79.5125.0719.8819.5419.6119.540.10
Inventories0.000.000.841.490.000.020.83
Sundry debtors64.2089.9276.7678.2952.1148.1331.22
Cash & bank balances5.3328.6944.0617.880.840.483.57
Loans & advances1.070.991.241.361.120.051.08
Total current assets70.6012012399.0254.0748.6836.70
Total current liabilities22.2913.3816.0824.0822.0322.169.79
Net working capital48.3110610774.9432.0426.5226.91
Total assets16916013710559.8446.7528.11
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash28.6844.0617.870.840.473.550.10
Net cash from operating activities43.87(7.60)(1.83)(7.07)8.8913.46(14.37)
Net cash from investing activities(67.77)(24.98)0.46(2.29)(6.87)(20.03)(0.28)
Net cash from financing activities0.5417.2127.5526.39(1.64)3.4918.10
Net change in cash(23.35)(15.37)26.1917.040.38(3.08)3.44
Closing cash5.3328.6944.0617.880.840.483.57
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+32.6%-13.1%-35.1%+6.8%+16.6%+90.4%-
EBITDA growth-70.9%-51.2%-68.3%-2.5%-9.0%+119.9%-
PBT growth+33.1%-5.4%-75.1%+13.9%-4.3%+124.3%+274.7%
Net income growth+43.1%-2.4%-77.2%+10.5%-3.0%+133.1%-
Revenue CAGR (3Y)-9.2%-15.6%-6.9%+33.3%+95.3%--
EBITDA CAGR (3Y)-61.1%-46.8%-34.5%+24.9%+123.0%--
Profitability & leverage
Net income margin+6.4%+5.9%+5.2%+15.0%+14.5%+17.4%+14.2%
Return on capital employed+6.1%+5.1%+6.0%+27.9%+37.2%+55.4%+58.4%
Return on net worth+4.0%+2.9%+3.4%+21.6%+29.0%+42.4%+41.1%
Debt / equity0.260.190.130.100.050.050.00
Long-term debt / equity0.010.010.020.010.000.000.00
Interest cover1,010.34104.1934.303.120.590.790.58
Efficiency & per share
Fixed asset turnover3.298.288.7619.9262.72179.11456.30
Inventory turnover0.00145.2160.26145.1510,129.00204.40109.95
Debtors turnover1.050.730.911.662.022.192.49
EPS (₹)0.930.650.6715.9314.6715.136.50
Dividend per share (₹)0.000.000.000.000.500.000.00
Book value per share (₹)24.0923.1621.6180.3557.9143.2528.11

To see the full year-wise statements and ratios of Balaxi Pharmaceuticals Limited, buy the company report.

Board of directors of Balaxi Pharmaceuticals Limited

Balaxi Pharmaceuticals has 6 current directors and 20 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Ashish MaheshwariManaging Director04 May 20179 Years 6 MonthsCurrent
Mangina Srinivas RaoDirector15 Sep 20206 Years 2 MonthsCurrent
Minoshi MaheshwariDirector04 May 20179 Years 6 MonthsCurrent
Kunal Mahendra BhaktaDirector04 May 20179 Years 6 MonthsCurrent
Gandhi GamjiDirector04 May 20179 Years 6 MonthsCurrent
Akshita SuranaDirector05 Sep 20242 Years 2 MonthsCurrent

Auditor

Balaxi Pharmaceuticals Limited is audited by P. Murali & Co. for the financial year 2025.

Auditor firmFinancial yearFirm registration number
P. Murali & Co.FY 2025007257S

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 66.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 2.60% and retail and other public shareholders hold 31.40%.

Promoters: 66.00%DII (Domestic Institutional): 2.60%Retail & Others: 31.40%
Sep 2026
QUARTER
66.00% Promoters
2.60% DII (Domestic Institutional)
31.40% Retail & Others
Promoter holding - history
Now 66.00% · Sep 2026High 66.00% · Dec 2025Low 66.00% · Dec 2025
65%65.5%66%66.5%67%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 66.00%Mar 2026: 66.00%Jun 2026: 66.00%Sep 2026: 66.00%66.00%66.00%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters66.00%66.00%66.00%66.00%
Public34.00%34.00%34.00%34.00%

Charges & borrowings

Open charges
₹36.44 Cr
Satisfied charges
₹34.29 Cr
Breakdown by lending institutions
Yes Bank Limited₹35.00 Cr
Axis Bank Limited₹1.44 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
20 Nov 2025101193014Axis Bank Limited₹1.44 CrOpen
16 Sep 2024100983181Yes Bank Limited₹35 CrOpen
26 Jul 2022100634052Others₹31 CrSatisfied
29 Jun 2021100459808Yes Bank Limited₹1 CrSatisfied
23 Jun 2020100349613Others₹21 LakhSatisfied

To see the full charge records of Balaxi Pharmaceuticals Limited, buy the company report.

Total charge records: 10 View all charges

Deals & funding

Balaxi Pharmaceuticals Limited has 13 deals on record (12 market trades, 1 funding round), with disclosed funding of ₹49.61 Cr; the latest was in March 2026.

Total deals
13
Market trades
12
Funding round
1
Disclosed funding
₹49.61 Cr

Deals on record (5 of 13)

WhenDealAmountParties
Dec 2025Market trade₹1.41 CrBuyer: Dulcet Advisory Private Limited
Seller: Dulcet Advisory Private Limited
Jul 2025Market trade₹1.46 CrBuyer: Dulcet Advisory Private Limited
Seller: Dulcet Advisory Private Limited
Jul 2025Market trade₹1.6 CrBuyer: Dulcet Advisory Private Limited
Apr 2025Market trade₹28.77 CrBuyer: Nexpact Limited, Multitude Growth Funds Limited, Padmavati Holdings Pvt Ltd
Seller: Unico Global Opportunities Fund Limited, Padmavati Holdings Pvt Ltd
Apr 2025Market trade₹3.03 CrBuyer: Shristi Investments Pvt Ltd
Seller: Unico Global Opportunities Fund Limited

To see the full deal history of Balaxi Pharmaceuticals Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Balaxi Pharmaceuticals Limited has 5 MSME Form 1 returns on record between 2023 and 2024, listing 368 overdue payments to 13 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 13)

SupplierAmount dueDue sinceReported on
M M Print & Pack
Lucent Biotech Limited
Glumex Pharmaceuticals Manufacturing Pvt Ltd.
Ion Healthcare Private Limited
National Laboratories Unit-Ii

To see the full MSME payment records of Balaxi Pharmaceuticals Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Balaxi Pharmaceuticals Limited has a workforce of 80 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.

Employee count
80
Active EPFO establishments
1
Employee growth
70.2%

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2026-2780
FY 2025-26
FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20
FY 2018-19

To see the full employee and EPFO history of Balaxi Pharmaceuticals Limited, buy the company report.

GST

Balaxi Pharmaceuticals has 2 GST registrations: 2 active.

Total GSTINs
2
Active
2
GSTINStateStatusRegistered on
36AABCA8305N1ZJTelanganaActive09 Jan 2018
36AABCA8305N2ZITelanganaActive20 Apr 2022

To see the full GST registrations and return filing status of Balaxi Pharmaceuticals Limited, buy the company report.

Recent activity

Balaxi Pharmaceuticals Limited has 38 board changes on record since 1959: 22 appointments and 16 cessations. The latest: Akshita Surana was appointed as Director on 05 Sep 2024.

Filing
Balaxi Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
Charges
A charge with Yes Bank Limited of Rs. 35.00 Cr registered on 16 Sep 2024 with Charge ID 100983181 was modified on 18 Mar 2026.
Charges
A charge with Axis Bank Limited amounted to Rs. 1.44 Cr with Charge ID 101193014 was registered on 20 Nov 2025.
AGM
Balaxi Pharmaceuticals Limited last Annual general meeting of members was held on 25 Aug 2025 as per latest MCA records.
Charges
A charge registered on 26 Jul 2022 via Charge ID 100634052 with Others was fully satisfied on 13 Nov 2024.
Charges
A charge with Yes Bank Limited amounted to Rs. 35.00 Cr with Charge ID 100983181 was registered on 16 Sep 2024.
Charges
A charge registered on 29 Jun 2021 via Charge ID 100459808 with Yes Bank Limited was fully satisfied on 05 Sep 2024.
Appointed
Akshita Surana was appointed as Director.
Ceased
Purnima Singh Singh Kamble ceased to be Director.
Charges
A charge registered on 23 Jun 2020 via Charge ID 100349613 with Others was fully satisfied on 28 Nov 2023.
Charges
A charge with Others amounted to Rs. 31.00 Cr with Charge ID 100634052 was registered on 26 Jul 2022.
Charges
A charge with Yes Bank Limited amounted to Rs. 1.00 Cr with Charge ID 100459808 was registered on 29 Jun 2021.

48 earlier events are in the company report.

Frequently asked questions

Balaxi Pharmaceuticals is an active public limited company based in Hyderabad, Telangana, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 28 September 1942 (84+ years old) and is registered under CIN L25191TG1942PLC121598. Listed on NSE: BALAXI.

Balaxi Pharmaceuticals reported revenue of ₹270.17 Cr for FY 2025-26 (down 7.7% YoY) based on consolidated financials.

Balaxi Pharmaceuticals has 6 current directors:

The latest financial statements of Balaxi Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 August 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Balaxi Pharmaceuticals is 36AABCA8305N1ZJ, registered in Telangana. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 36AABCA8305N2ZI (Telangana).

The CIN (Corporate Identification Number) of Balaxi Pharmaceuticals is L25191TG1942PLC121598. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Balaxi Pharmaceuticals is a listed company as per MCA records. Its shares are listed on NSE (symbol: BALAXI).

Balaxi Pharmaceuticals has 1 court case on record: 1 filed by the company. 1 is pending.

Balaxi Pharmaceuticals was incorporated on 28 September 1942, making it 84+ years old. It is registered with the Registrar of Companies, Hyderabad.

Balaxi Pharmaceuticals has 13 deals on record (12 market trades, 1 funding round), with disclosed funding of ₹49.61 Cr; the latest was in March 2026.

Akshita Surana was appointed as Director on 05 Sep 2024. Purnima Singh Singh Kamble ceased to be Director on 08 May 2024. Purnima Singh Singh Kamble was appointed as Director on 26 Mar 2021. Balaxi Pharmaceuticals has 38 board changes on record in total.